News
Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $93 from $74 and keeps an Overweight rating on the shares. Consistent with the firm’s longitudinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback